eli lilly and company retatrutide People lost up to 85 pounds on Lilly's experimental weight loss drug, says Lilly's triple agonist, retatrutide, delivered

Prescribed by healthcare providers, they mimic the effects of the natural GLP-1 hormone, promoting satiety (feeling full) and regulating blood sugar levels

Data were analyzed based on three criteria: acute administration (injection 1), repeated administration (injections 1, 3, and 8), and post-treatment effects (days 1 and 3 post-treatment)

10 In addition to case reports and guidance from various professional associations, there have been multiple retrospective reviews of patients taking GLP-1 receptor agonists undergoing endoscopy that suggest an increased risk of retained gastric contents in patients taking these medications

DOI : 10.3389/fphar.2025.1702448